Basis: Latest reported fiscal year. Source: stored company filings and market data; unavailable inputs remain N/A.
Is the return on equity (ROE) high or low?
The return on equity (ROE) of -35444.23% is 484% below its 5-year average of -6066.76%, near the low end of its 5-year range (-35444.23%–-76.52%).
As of the fiscal period ended Wednesday, December 31, 2025. 98.31% below its 12-month average of -17872.82%.
Annual fiscal-year return on equity; no daily interpolation. Historical series through 2025-12-31.
RETURN ON EQUITY (ROE)
-35444.23%
RETURN ON EQUITY (ROE) AVG TTM
-17872.82%
RETURN ON EQUITY (ROE) AVG 3Y
-9061.56%
RETURN ON EQUITY (ROE) AVG 5Y
-6066.76%
RETURN ON EQUITY (ROE) AVG 10Y
-3421.21%
RETURN ON EQUITY (ROE) AVG 15Y
-100.37%
RETURN ON EQUITY (ROE) AVG 20Y
-146.59%
CURRENT VS TTM AVG
-98.31%
CURRENT VS 3Y AVG
-291.15%
CURRENT VS 5Y AVG
-484.24%
CURRENT VS 10Y AVG
-936.01%
CURRENT VS 15Y AVG
-35214.65%
CURRENT VS 20Y AVG
-24078.57%
SECTOR MEDIAN · HEALTHCARE
-42.01%
median of 754 covered companies
CURRENT VS SECTOR MEDIAN
-84270.94%
vs the sector median at left
Tiziana Life Sciences Ltd
Market Cap
$70.63M
Return on Equity (ROE)
-35444.23%
TTM Avg
-17872.82%
3Y Avg
-9061.56%
5Y Avg
-6066.76%
Market Cap
$71.23M
Return on Equity (ROE)
-178.06%
TTM Avg
-193.35%
3Y Avg
-164.22%
5Y Avg
-125.75%
Market Cap
$69.61M
Return on Equity (ROE)
-29.15%
TTM Avg
47.40%
3Y Avg
90.52%
5Y Avg
62.16%
Market Cap
$72.32M
Return on Equity (ROE)
-724.01%
TTM Avg
352.19%
3Y Avg
76.05%
5Y Avg
9.78%
Market Cap
$68.90M
Return on Equity (ROE)
16.70%
TTM Avg
-67.07%
3Y Avg
-43.48%
5Y Avg
-55.81%
Market Cap
$72.83M
Return on Equity (ROE)
-250.39%
TTM Avg
-122.53%
3Y Avg
-92.00%
5Y Avg
-67.18%
Market Cap
$68.10M
Return on Equity (ROE)
68.12%
TTM Avg
-94.32%
3Y Avg
-166.28%
5Y Avg
-128.51%
Market Cap
$73.27M
Return on Equity (ROE)
-94.81%
TTM Avg
-84.90%
3Y Avg
-70.34%
5Y Avg
-58.48%
Market Cap
$67.52M
Return on Equity (ROE)
-38.55%
TTM Avg
-81.03%
3Y Avg
-175.38%
5Y Avg
-133.71%
| NAME | MARKET CAP | RETURN ON EQUITY (ROE) | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Tiziana Life Sciences Ltd (TLSA) | $70.63M | -35444.23% | -17872.82% | -9061.56% | -6066.76% |
| Gain Therapeutics, Inc. (GANX)vs › | $71.23M | -178.06% | -193.35% | -164.22% | -125.75% |
| Champions Oncology, Inc. (CSBR)vs › | $69.61M | -29.15% | 47.40% | 90.52% | 62.16% |
| Verrica Pharmaceuticals Inc. (VRCA)vs › | $72.32M | -724.01% | 352.19% | 76.05% | 9.78% |
| Spero Therapeutics, Inc. (SPRO)vs › | $68.90M | 16.70% | -67.07% | -43.48% | -55.81% |
| MindWalk Holdings Corp. (HYFT)vs › | $72.83M | -250.39% | -122.53% | -92.00% | -67.18% |
| Fortress Biotech, Inc. (FBIO)vs › | $68.10M | 68.12% | -94.32% | -166.28% | -128.51% |
| Hyperfine, Inc. (HYPR)vs › | $73.27M | -94.81% | -84.90% | -70.34% | -58.48% |
| iBio, Inc. (IBIO)vs › | $67.52M | -38.55% | -81.03% | -175.38% | -133.71% |
| Pulmonx Corporation (LUNG)vs › | $75.18M | -122.76% | -82.75% | -63.80% | -49.10% |
ROE
-35444.2%
ROA
-160.3%
ROE = Net Income / Total Shareholders' Equity
Return on equity measures how efficiently a company generates profit from shareholders' equity. Higher ROE indicates better capital efficiency.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | RETURN ON EQUITY (ROE) |
|---|---|
| 2025-12-31 | -35444.23% |
| 2024-12-31 | -301.40% |
| 2023-12-31 | -403.93% |
| 2022-12-31 | -96.69% |
| 2021-12-31 | -76.52% |
| 2020-12-31 | -77.76% |
| 2019-12-31 | 224.03% |
| 2018-12-31 | -1540.08% |
| 2017-12-31 | 402.26% |
| 2016-12-31 | -217.50% |
| 2015-12-31 | -101.51% |
| 2014-12-31 | -197.52% |
| 2013-12-31 | 191.78% |
| 2012-12-31 | 2120.00% |
| 2011-12-31 | -148.19% |
| 2010-12-31 | -501.82% |
| 2009-12-31 | -60.18% |
| 2008-12-31 | -106.64% |
| 2007-12-31 | -99.06% |
| 2006-12-31 | -89.62% |
| 2005-12-31 | -75.79% |
| 2004-12-31 | -39.18% |
| 2003-12-31 | -64.82% |
| 2002-12-31 | -104.58% |
| 2001-12-31 | -78.49% |
| 2000-12-31 | -56.60% |
| 1999-12-31 | -27.91% |
| 1998-12-31 | -12.07% |
